Research has shown that absence epilepsy is associated with an unusually high activity of T-type calcium channels. CX-8998 is a drug that modulates T-type calcium channels in the nervous system. T-WAVE is a phase 2 clinical trial assessing CX-8998 as a potential treatment for absence epilepsy. The purpose of this study is to learn whether CX-8998 has any side effects and whether taking CX-8998 changes how often absence seizures happen. The study will also measure how quickly the drug enters and leaves the body.

 

---

To learn more about the T-WAVE Phase 2 clinical trial, visit https://twavestudy.com/

---

 

Enrollment has been completed for more than 90 patients with Essential Tremor in the T-CALM Phase 2 clinical trial. The main purpose of this trial is to determine if the experimental drug, CX-8998, will help reduce tremors. Essential tremor may result from changes in the electrical activity in certain regions of the brain. There are scientific reasons to believe that giving CX-8998 may correct these changes and reduce the severity of the tremor. Other goals of this trial are to learn about the side effects of CX-8998, to measure the possible effects of CX-8998 on quality of life, to investigate further how this drug works and to measure the levels of the drug and its breakdown products in the blood.

 

---

To learn more about the T-CALM Phase 2 clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03101241?term=cavion&rank=3(ClinicalTrials.gov Identifier: NCT03101241)

---